News Home

Where Does Wall Street Think Crispr Therapeutics AG (CRSP) Stock Will Go?

Wednesday, May 25, 2022 04:03 PM | InvestorsObserver Analysts
Where Does Wall Street Think Crispr Therapeutics AG (CRSP) Stock Will Go?

Wall Street is positive on Crispr Therapeutics AG (CRSP). On average, analysts give CRSP a Strong Buy rating. The average price target is $137.8, which means analysts expect the stock to climb by 153.17% over the next twelve months. That average ranking earns CRSP an Analyst Rating of 51, which is better than 51% of stocks based on data compiled by InvestorsObserver.

Overall Score - 4.4
Wall Street analysts are rating CRSP a Strong Buy today. Find out what this means to you and get the rest of the rankings on CRSP!

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported. InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With Crispr Therapeutics AG Stock Today?

Crispr Therapeutics AG (CRSP) stock is trading at $54.43 as of 3:57 PM on Wednesday, May 25, a rise of $2.04, or 3.9% from the previous closing price of $52.38. The stock has traded between $51.55 and $54.94 so far today. Volume today is low. So far 943,324 shares have traded compared to average volume of 1,349,455 shares. Click Here to get the full Stock Report for Crispr Therapeutics AG stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App